Illinois’ governor admitted he used an expensive GLP-1 drug while his administration put taxpayers on the hook for broad GLP-1 coverage for tens of thousands of state employees.
Story Snapshot
- Governor J.B. Pritzker said he used a GLP-1 and that Illinois covers GLP-1s for 55,000 state employees.
- Illinois expanded coverage for drugs like Wegovy and Mounjaro starting in 2023 and 2024.
- The expanded benefit cost Illinois $147 million in fiscal year 2025, with higher first-year estimates reported elsewhere.
- Public records do not yet show if taxpayers directly paid Pritzker’s personal prescription costs.
Pritzker Confirms Personal Use And Broad State Coverage
Governor J.B. Pritzker confirmed he has taken a GLP-1 drug since 2024 and said Illinois’ state plan covers GLP-1s for about 55,000 state employees. He reported losing 80 pounds and tied his coverage to the state insurance plan. He also said the policy was a general employee benefit, not crafted for him. His remarks came as media focused on his health and the scope of the state’s GLP-1 coverage for workers and dependents.
Illinois expanded coverage for GLP-1 medications under the state group health insurance program in July 2023. Reports say the expansion included popular brands like Wegovy, Mounjaro, and Ozempic. Later updates widened eligibility to adults with prediabetes, gestational diabetes, or obesity. That means the plan does not limit coverage to diabetes treatment only. It opens a costly class of drugs to weight-loss use for many employees who meet set criteria.
Taxpayer Costs Rise As Coverage Widens
NPR Illinois reported the expanded coverage cost the state $147 million in fiscal year 2025. That is real money for a single benefit line in one year. Other reporting noted the governor’s office had projected even higher first-year costs, and some economists warned the tab could climb much more as use grows. These figures highlight why many public plans still restrict GLP-1s for weight loss due to steep pharmacy costs.
Governor Pritzker stated he put the policy in place before he expected to take a GLP-1 himself and framed it as a health-driven decision. He also argued the benefit could save taxpayers money over time. But the current record does not include a completed actuarial audit that proves savings against near-term spending. Until a formal study is public, Illinois families only see the direct price tag and the expanding eligibility that can keep costs rising.
What We Know—and What We Do Not
The governor said his medication is covered under the state plan. The coverage applies to tens of thousands of workers. The program added weight-loss eligibility, not just diabetes treatment. The cost to the state is already large and could grow with more uptake. However, no public document shows how the governor’s own premiums, copays, or claims were paid. That gap means we cannot yet prove whether taxpayers subsidized his personal prescription.
Illinois can clear this up with basic, privacy-safe records. The Department of Central Management Services could release plan amendments authorizing GLP-1 weight-loss coverage and the fiscal rationale. The state could publish an actuarial analysis that weighs drug costs against avoided hospitalizations and diabetes complications. De-identified utilization data could show how many members use GLP-1s for weight loss versus diabetes and what the trend lines look like.
Why This Matters For Working Families
Taxpayers already battle high prices, rising insurance premiums, and tight budgets. When a powerful officeholder uses a high-cost drug while expanding public coverage for that same drug class, people deserve transparency. Families want to know if this is a fair, affordable plan or another elite perk they must fund. They also want choices, not mandates, and a system that rewards healthy habits without saddling them with outsized pharmacy bills they can never control.
Illinois Gov. J.B. Pritzker invited US into his private residence at the Governor's Mansion to share something he's kept private until now.
For the last two years, Pritzker has used a GLP-1 medication to lose 80 pounds, a decision shaped by losing his father to a heart attack… pic.twitter.com/KQFCuCZ6Lu
— David Begnaud (@DavidBegnaud) September 21, 2026
President Trump’s 2025 federal pricing push aimed to reset GLP-1 costs for public programs, but state employee plans still face hard trade-offs. Illinois can lead by showing its math and making sure the benefit does not crowd out core services or force premium hikes. A simple pledge can help: publish the actuarial study, cap plan spending growth, and put any savings in writing for taxpayers to see. Sunlight and discipline protect both health and wallets.
